CD19 and neoplasm: Furthermore, multi-target CAR-T cell therapies were created by mixing multiple CAR-T cells with a single CAR to target a different tumor-specific antigen such as BCMA + CD19, BCMA + GPRC5D, BCMA + TACO, and BCMA + SLAMF7 [159,161].